These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 19031951)

  • 1. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
    Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
    Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
    Schneider J; Philipp M; Salewski L; Velcovsky HG
    Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
    Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
    Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
    Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
    Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis.
    Boher JM; Pujol JL; Grenier J; Daurès JP
    Br J Cancer; 1999 Mar; 79(9-10):1419-27. PubMed ID: 10188885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study].
    Emin Erbaycu A; Gunduz A; Batum O; Zeren Ucar Z; Tuksavul F; Zeki Guclu S
    Arch Bronconeumol; 2010 Jul; 46(7):364-9. PubMed ID: 20537457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.
    Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H
    Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC.
    Ebert W; Muley T; Trainer C; Dienemann H; Drings P
    Anticancer Res; 2002; 22(2B):1083-9. PubMed ID: 12168905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tumor markers in lung cancer].
    Niho S; Shinkai T
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic and prognostic value of ProGRP in lung cancer.
    Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
    Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.
    Bonner JA; Sloan JA; Rowland KM; Klee GG; Kugler JW; Mailliard JA; Wiesenfeld M; Krook JE; Maksymiuk AW; Shaw EG; Marks RS; Perez EA
    Clin Cancer Res; 2000 Feb; 6(2):597-601. PubMed ID: 10690544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-6 and VEGF in small cell lung cancer patients.
    Wójcik E; Jakubowicz J; Skotnicki P; Sas-Korczyńska B; Kulpa JK
    Anticancer Res; 2010 May; 30(5):1773-8. PubMed ID: 20592377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
    Ebert W; Hoppe M; Muley T; Drings P
    Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer.
    Okusaka T; Eguchi K; Kasai T; Kurata T; Yamamoto N; Ohe Y; Tamura T; Shinkai T; Saijo N
    Clin Cancer Res; 1997 Jan; 3(1):123-7. PubMed ID: 9815547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
    Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
    Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical significance of ProGRP31-98 in patients with small-cell lung cancer].
    Yang J; Li R; Li A
    Zhonghua Zhong Liu Za Zhi; 2000 May; 22(3):216-8. PubMed ID: 11778234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.